Warning! GuruFocus detected
4 Severe warning signs
with TOI.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
The Oncology Institute Inc
NAICS : 621498
SIC : 8093
ISIN : US68236X1000
Description
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.39 | |||||
| Equity-to-Asset | 0.09 | |||||
| Debt-to-Equity | 7.94 | |||||
| Debt-to-EBITDA | -2.19 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0.14 | |||||
| Beneish M-Score | -3.18 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.8 | |||||
| 3-Year EBITDA Growth Rate | -76.1 | |||||
| 3-Year EPS without NRI Growth Rate | -47.3 | |||||
| 3-Year FCF Growth Rate | -269.3 | |||||
| 3-Year Book Growth Rate | 20.8 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 87.88 | |||||
| 9-Day RSI | 73.09 | |||||
| 14-Day RSI | 65.7 | |||||
| 3-1 Month Momentum % | 323.56 | |||||
| 6-1 Month Momentum % | 203.72 | |||||
| 12-1 Month Momentum % | -34.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.49 | |||||
| Quick Ratio | 2.27 | |||||
| Cash Ratio | 1.01 | |||||
| Days Inventory | 13.21 | |||||
| Days Sales Outstanding | 49.72 | |||||
| Days Payable | 20 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.8 | |||||
| Shareholder Yield % | -11.36 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 14.18 | |||||
| Operating Margin % | -16.75 | |||||
| Net Margin % | -18.54 | |||||
| FCF Margin % | -9.9 | |||||
| ROE % | -163.45 | |||||
| ROA % | -35.44 | |||||
| ROIC % | -55.92 | |||||
| 3-Year ROIIC % | -88.42 | |||||
| ROC (Joel Greenblatt) % | -83.78 | |||||
| ROCE % | -39.12 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.19 | |||||
| PB Ratio | 4.74 | |||||
| EV-to-EBIT | -2.38 | |||||
| EV-to-EBITDA | -2.64 | |||||
| EV-to-Revenue | 0.39 | |||||
| EV-to-FCF | -3.95 | |||||
| Price-to-GF-Value | 0.39 | |||||
| Earnings Yield (Greenblatt) % | -42.02 | |||||
| FCF Yield % | -49.84 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TOI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
The Oncology Institute Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 378.933 | ||
| EPS (TTM) ($) | -0.78 | ||
| Beta | 0.07 | ||
| 3-Year Sharpe Ratio | 0.26 | ||
| 3-Year Sortino Ratio | 0.56 | ||
| Volatility % | 267.37 | ||
| 14-Day RSI | 65.7 | ||
| 14-Day ATR ($) | 0.118542 | ||
| 20-Day SMA ($) | 0.76862 | ||
| 12-1 Month Momentum % | -34.57 | ||
| 52-Week Range ($) | 0.1253 - 1.89 | ||
| Shares Outstanding (Mil) | 75.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
The Oncology Institute Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
The Oncology Institute Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
The Oncology Institute Inc Frequently Asked Questions
What is The Oncology Institute Inc(TOI)'s stock price today?
The current price of TOI is $1.00. The 52 week high of TOI is $1.89 and 52 week low is $0.13.
When is next earnings date of The Oncology Institute Inc(TOI)?
The next earnings date of The Oncology Institute Inc(TOI) is 2025-03-25.
Does The Oncology Institute Inc(TOI) pay dividends? If so, how much?
The Oncology Institute Inc(TOI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers